Latest News - Danaher
Top Corporates Hub
Danaher
Jim Cramer on Danaher: “I Don’t Want You Anywhere Near That One”
10.07.2026 12:01
Danaher Corporation (NYSE:DHR) was among the stocks Jim Cramer discussed during Mad Money, as he called the growing wave of stock offerings and debt issuance a threat to the bull market. Expressing their wish to diversify, a caller inquired about the stock, and Cramer commented: Danaher’s been a huge disappointment, and we managed to get […]
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
10.07.2026 09:26
Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.
Beckman Coulter Diagnostics Expands Alzheimer's Portfolio with CE-Marked p-Tau217 Blood Test and New High-Specificity Research Assay
07.07.2026 07:00
Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Access p-Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline. The company also introduced its high-specificity Access BD-pTau217 Research Use Only (RUO) assay at the Alzheimer's Association International Conference (AAIC) 2026 in London.
Evercore ISI Group Maintains Outperform on Danaher, Lowers Price Target to $230
06.07.2026 12:08
Evercore ISI Group analyst Vijay Kumar maintains Danaher (NYSE:DHR) with a Outperform and lowers the price target from $232 to $230.
Danaher (DHR) Completes $9.9B Acquisition of Masimo Corporation
29.06.2026 05:28
Danaher Corporation (NYSE:DHR) is one of the best long term stocks to buy according to hedge funds. On June 10, Danaher completed its acquisition of Masimo Corporation, a specialist in pulse oximetry and patient monitoring solutions. Masimo will now function as a standalone operating company within Danaher’s Diagnostics segment, retaining its original brand identity while […]
Is Danaher (DHR) Using Masimo’s New FDA-Cleared AI Tool To Redefine Its Medtech Edge?
25.06.2026 03:16
On 22 June 2026, Masimo, a Danaher company, received FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression detection feature integrated into its Radius VSM wearable continuous patient monitor. This clearance highlights how Danaher is pushing pulse oximetry beyond basic vital sign tracking toward AI-driven, clinically actionable insights in hospital monitoring. Next, we’ll examine how integrating AI-based opioid-induced respiratory depression detection into Radius VSM...
VTRS vs. DHR: Which Stock Is the Better Value Option?
23.06.2026 15:40
VTRS vs. DHR: Which Stock Is the Better Value Option?
Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection on Radius VSM® to Help Identify Respiratory Risk Sooner
22.06.2026 12:00
IRVINE, Calif., June 22, 2026--Masimo smartSET™-powered, AI-enabled OIRD detection has received FDA 510(k) clearance for the Radius VSM® wearable continuous patient monitor.
Twist Bioscience: Huge Downside, With Little Hope Of Profits
18.06.2026 13:01
Twist Bioscience (TWST) looks overvalued at 11x revenue with ongoing losses; our fair value is $38 (50% downside). Read more macro analysis here.
Danaher Corporation’s (DHR) Recovery Fell Short of Investor Expectations
15.06.2026 14:48
Madison Investments, an investment advisor, released its first-quarter 2026 investor letter for the “Madison Large Cap Fund”. A copy of the letter is available to download here. The Madison Large Cap Fund (Class I) declined 2.7% in the quarter, outperforming the S&P 500’s -4.33% return. The fund focuses on long-term capital appreciation. The quarter saw […]
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
15.06.2026 13:32
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Piper Sandler Begins Coverage of Danaher (DHR) While Waiting for New Growth Catalysts
15.06.2026 05:09
Danaher Corporation (NYSE:DHR) is included among Billionaire Larry Robbins’ 10 Dividend Stock Picks. On June 11, Piper Sandler initiated coverage of Danaher Corporation (NYSE:DHR) with a Neutral rating and a $200 price target. The firm launched coverage of the life science tools sector with what it described as a “feet in the shallow end of […]
Implied Volatility Surging for Danaher Stock Options
12.06.2026 12:23
Investors need to pay close attention to DHR stock based on the movements in the options market lately.
Cepheid Delivers Xpert® Hemorrhagic Fever Panel Tests to Africa to Address Diagnostic Gaps in Ebola Bundibugyo Outbreak
12.06.2026 10:00
SUNNYVALE, Calif., June 12, 2026--Cepheid, a Danaher company, today announced it has donated an initial shipment of Xpert® Hemorrhagic Fever panel tests to support the diagnostic response to the Ebola Bundibugyo (BDBV) outbreak in the Democratic Republic of the Congo (DRC) and Uganda. The World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern on May 17, 2026.1
Danaher Closes Acquisition of Masimo; Maintains Q2, 2026 Outlook
10.06.2026 13:55
Danaher (DHR) said Wednesday it has completed its acquisition of Masimo (MASI), a speciality diagnos
Danaher Completes Acquisition of Masimo Corporation
10.06.2026 12:55
Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.
Is It Time To Reassess Danaher (DHR) After Its Recent Share Price Weakness?
02.06.2026 16:09
If you are wondering whether Danaher stock is starting to look more interesting at its current price, this breakdown will help you judge if the valuation really stacks up. Over the short term, the stock has risen 4.6% over the past week and 2.7% over the past month. Year to date, the share price is down 21.9% and the 1-year return is down 4.3% from a last close of US$179.87. Recent coverage has focused on how investors are reassessing large healthcare and life sciences companies as interest...
Teladoc (TDOC) Up 23.9% Since Last Earnings Report: Can It Continue?
29.05.2026 15:30
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A Look At Danaher (DHR) Valuation After Strong Q1 Earnings Beat And Raised Guidance
23.05.2026 04:25
Danaher (DHR) drew fresh attention after strong first quarter results, with adjusted earnings per share ahead of expectations and full year guidance raised. This combination supported renewed interest in the stock. See our latest analysis for Danaher. Despite the positive Q1 surprise and raised guidance, Danaher’s share price return is still down 25.35% year to date and the 1 year total shareholder return is down 6.15%. Recent momentum therefore remains fragile. If earnings driven moves in...